Logo

Roche Highlights its Bispecific Antibody Portfolio Across a Range of Blood Cancers at ASH 2020

Share this

Roche Highlights its Bispecific Antibody Portfolio Across a Range of Blood Cancers at ASH 2020

Shots:

  • The company presented the new data of its T-cell engaging bispecific Abs- mosunetuzumab- glofitamab and cevostamab at ASH 2020- demonstrating encouraging activity across multiple types of blood cancer
  • Roche divulges that its mosunetuzumab & glofitamab showed promising responses across multiple types of NHL- including R/R FL & DLBCL- reinforcing from the P-I/Ib GO29781 study results in R/R FL- that showed 51.6% of patients achieved a CR when treated with mosunetuzumab
  • Beyond r/r setting- mosunetuzumab & glofitamab are also being evaluated in 1L DLBCL. Additionally- Roche has presented the data of cevostamab that showed a 53% ORR rate in heavily pre-treated patients with MM

 ­ Ref: GlobeNewswire | Image: Roche 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions